Abstracts tagged "Autoimmune diseases and rheumatoid arthritis"

Abstract Number: 992 • 2019 ACR/ARP Annual Meeting
Identification of CJ-15314, a Novel Highly Selective JAK1 Inhibitor, for the Treatment of Rheumatoid Arthritis
So Young Ki¹, Dongkyu Kim ¹, Juhyun Lee ¹, Byoung Seok Moon ¹ and Shin-Young Ryu ¹, ¹CJ Healthcare, Icheon-si, Republic of Korea
Background/Purpose: Janus kinases (JAKs) play critical roles in mediating various cytokine signaling. First-generation non-selective JAK inhibitors such as tofacitinib and baricitinib are widely used for…
Abstract Number: 2214 • 2013 ACR/ARHP Annual Meeting
STAT3 Blockade Suppresses Autoimmune Arthritis In Mice Via The Reciprocal Regulation Of Treg and Th17 Cells
Jennifer Lee¹, Jae Ho Lee¹, Seung Min Jung², Young Sun Suh¹, Jung Hee Koh¹, Soo Young Lee³, Dae Chul Jeong⁴, Mi-La Cho⁵, Seung-Ki Kwok¹, Ji Hyeon Ju¹, Kyung-Su Park¹ and Sung-Hwan Park⁶, ¹Division of Rheumatology, Department of Internal Medicine, School of Medicine, The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, South Korea, ²Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea, ³Department of Pediatrics, School of Medicine, The Catholic University of Korea, Incheon St. Mary's Hospital, Incheon, South Korea, ⁴Division of Rheumatology, Department of Pediatrics, School of Medicine, The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, South Korea, ⁵Rheumatism Research Center, Catholic Research Institute of Medical Science, Catholic University of Korea, Seoul, South Korea, ⁶Rheumatism Research Center, Catholic Research Institute of Medical Science, The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, South Korea
Background/Purpose: IL-6-mediated STAT3 signaling which is essential to Th17 differentiation plays the central role in the pathogenesis of rheumatoid arthritis. To investigate the molecular mechanism…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].